ArticleReviews in cardiovascular medicine2025
Development Track of Compliance With Dual Antiplatelet Therapy and Analysis of Potential Categories in Patients With ACS After PCI.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the potential categories of compliance development track of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) using growth mixture modeling (GMM) to analyze its predictive factors, providing evidence for dynamic adherence monitoring and tailored interventions. Methods: A total of 150 patients with ACS after PCI were selected by convenience sampling. Patients were studied using Self-Efficacy for Appropriate Medication Use Scale (SEAMS), family APGAR index (APGAR), Generalized Anxiety Disorder-2 (GAD-2), and Patient Health Questionnaire-2 (PHQ-2) at baseline. The compliance of patients with DAPT was assessed using Morisky Medication Adherence Scales-8 (MMAS-8) at 1, 3, 6, 9, and 12 months after discharge. The mixed model of latent variable growth was used to identify the development track of compliance. Multiple logistic regression was used to analyze the predictive factors of different development track categories. Results: Two development track categories of DAPT compliance in patients with ACS after PCI were identified in the low compliance-decreased group (7.41%) and the persistent high compliance group (92.59%). Multivariate logistic regression analysis showed that age ≥60 years, body mass index (BMI), and the family APGAR index were the predictive factors of different development track categories of DAPT compliance in patients with ACS after PCI. Conclusion: Significant population heterogeneity was observed in the development track of DAPT in ACS patients within 12 months after PCI. The compliance of most patients remained stable, and only a few remained at a low level and showed a significant downward trend. Based on these predictive factors, healthcare personnel can identify patients in the low compliance-decreased group early and implement targeted and specific interventions to improve DAPT compliance of ACS patients after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.